Figure 4. Marimastat reversed hepatic steatosis and improved surrogate markers for insulin sensitivity in diet-induced obese mice as well as in ob/ob animals.

Mean hepatic fat fraction as measured by MR spectroscopy was decreased following Marimastat treatment (A). Marimastat treatment resulted in a decrease of plasma alanine aminotransferase levels (B), indicating decreased hepatic injury. Glucose (C) and insulin (D) levels in the fasted state, as well as log of homeostasis assessment (log(HOMA); E) and Quantitative insulin-sensitivity check index (QUICKI; F) as surrogate markers for insulin sensitivity were improved following treatment with Marimastat. Values represent the mean ± SEM. Statistical significance is calculated between the VEH and MAR animals (n = 5 C57BL/6 and n = 4 ob/ob animals per group; *, P<0.05; **, P<0.01; ***, P<0.001).